Head-to-head evidence
Culmerciclib vs SPH4336
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK2/4/6/CDK4 · full HR+/HER2- Metastatic Breast Cancer pipeline
Culmerciclib
Developed by Sino Biopharmaceutical
NCT05375461 · Phase 3 · completed
The study randomized 293 participants to TQB3616 plus fulvestrant or placebo plus fulvestrant and used quadruple blinding, with progression-free survival as the primary clinical endpoint. Because the primary comparison has not yet been reported, the trial provides a well-controlled but currently incomplete evidence record.
Next expected readout: December 2026 · NCT06202261 (registry estimate)
SPH4336
Developed by Shanghai Pharmaceuticals Holding
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05860465 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Culmerciclib's landscape · SPH4336's landscape